ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

DCE Board Approves Study of Breast Cancer On Long Island

June 17, 1994

Guideline Adherence Improves Early Breast Cancer Survival

August 27, 2004

Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia

October 31, 2003

White House Backs Down FY 86 Cuts, Says Now They Will Be Limited To Trimming Indirect Costs

January 10, 1986

Studies of Oncotype DX Test Presented at ASCO Symposium

January 31, 2014

MD Anderson Completes $500 Million Research Endowment

September 24, 2010